On June 1, 2026, the European Medicines Agency\u2019s Guideline on the Development and Manufacture of Synthetic Peptides officially took effect. This is the first EU-wide regulatory framework built specifically for synthetic peptide active substances. Before this, synthetic peptides fell in a regulatory gap between the rules for small molecules and the rules for biologics. The new document closes that gap.
Source: EMA Guideline PDF | EMA Concept Paper
The EMA\u2019s Quality Working Party published a concept paper in 2022 and a draft guideline for consultation in 2023. The CHMP adopted the final text on December 1, 2025, with effect from June 1, 2026. Here is what the document requires and why it matters for anyone buying or selling peptide products.
The Regulatory Gap They Were Trying to Fill
The EMA\u2019s own concept paper put it plainly: "Synthetic peptides are at the interface of small molecules and proteins and, from a quality point of view, specific considerations apply to this class of therapeutics. Currently there is no guideline which reflects the quality requirements for regulators and industry on synthetic peptides."
The new guideline sets requirements for manufacturing process description, starting material selection, characterization approaches, impurity profiling, and purity control. It covers both solid-phase peptide synthesis (SPPS) and solution-phase synthesis (LPPS), including fragment condensation for longer peptides where SPPS alone cannot deliver acceptable yields.
Manufacturing Process Requirements
Companies filing for approval must provide a step-by-step description of their synthesis process with controls at every critical step: coupling efficiency, deprotection, cleavage, and purification. For SPPS, the guideline specifically addresses how to define batches and how to handle splitting, pooling, and re-processing steps during purification. This is significantly more detailed than prior guidance.
The guideline references ICH Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Development and Manufacture of Drug Substances) as the framework, with peptide-specific additions for in-process controls.
Impurity Profiling
This is the most important section of the document. Purity is described as "one of the most important critical quality attributes (CQAs) for synthetic peptides." The guideline splits impurities into two categories: peptide-related (truncated sequences, deletion peptides, epimerized sequences, oxidized variants, aggregation species) and non-peptide (process reagents, residual solvents, elemental impurities, potential genotoxic impurities).
A 2014 study by D\u2019Hondt et al. documented 11 categories of process-related impurities in synthetic peptides. Some of those impurities can affect biological activity at levels below 0.5%. Peptides fall outside ICH Q3A, so peptide-related impurities follow the thresholds in the Ph. Eur. general monograph on synthetic peptides: report above 0.1%, identify above 0.5% and qualify above 1.0%.
Orthogonal purity methods are recommended. The concern is that a single HPLC method may not resolve multiple closely related impurity species that coelute with the main peak. Running a second, orthogonal method reduces that risk.
For research-grade peptides that fall outside the guideline\u2019s direct scope, the analytical standards it formalizes for drug-grade material are increasingly being adopted voluntarily. A practical minimum standard has emerged: third-party COA with HPLC purity (98%+), LC-MS identity confirmation, lot number matching the vial, and impurity reporting.
Counter-Ion Control
Synthetic peptides pick up counter-ions during cleavage and purification. The two most common are trifluoroacetic acid (TFA) and acetate. The guideline requires the counter-ion to be defined and its amount controlled in the active substance specification, with a justified upper limit. It does not set a single numeric limit for TFA.
Stability Testing
Peptides are less stable than small molecules. They are susceptible to hydrolysis, deamidation, oxidation, and aggregation. The guideline requires stress testing under conditions relevant to the peptide\u2019s intended storage, using analytical methods capable of resolving the active peptide from its degradation products. The FDA\u2019s NDA-stage expectation is data from at least three batches for a minimum of 12 months under long-term storage and six months under accelerated conditions.
What This Means for Buyers
The EMA guideline applies to any synthetic peptide product seeking EU marketing authorization. Like other EMA scientific guidelines it is not legally binding, but applicants must fully justify any deviation from it, so CDMOs and API manufacturers supplying the EU market are expected to align with it. But the effects are broader than that.
As EU manufacturers raise their analytical bar, those standards propagate through the global supply chain. A supplier that can produce lot-specific COA with HPLC chromatograms, LC-MS confirmation, chiral purity data, and residual solvent analysis is operating at a different level than one that provides only a purity percentage. The guideline gives buyers a reference framework for what \u201Cgood documentation\u201D actually looks like.
For 503A compounding and research-grade peptides, the guideline is not directly enforceable. But the methods it formalizes are increasingly used as voluntary quality benchmarks. If a supplier cannot produce documentation at this level, it is worth asking why.